Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

131 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. Since transplant recipients are at risk for CMV or have evidence of infection with CMV, they are given an antiviral drug (usually ganciclovir or valganciclovir). Despite this, there are a chance that CMV infection may cause problems in the future. The purpose of this study is to assess how well patients'immune systems responds to the CMV virus, so that in the future it may be possible to predict which patients are at highest risk of CMV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

NCT02784756

Cytomegalovirus Viraemia

COMPLETED NA

Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)

NCT06341543

Cytomegalovirus Infections Heart Transplantation Kidney Transplantation +2 more

RECRUITING NA

Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.

NCT02064699

Renal Transplant Recipient Immunized Against the Cytomegalovirus

TERMINATED

Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients

NCT00436384

Transplant

COMPLETED

Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates

NCT00677482

Transplant

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CMV is the most common viral infection after solid organ transplantation (SOT) and is associated with significant morbidity1. Without prophylaxis, most CMV disease occurs in the first 3 months post-transplant during the period of intense of immunosuppresion.2 SOT recipients at the greatest risk are those that are seronegative recipients of organs from seropositive donors (CMV D+/R-).3, 4 Antiviral agents have proven to be useful in the prevention of CMV infection and disease in SOT recipients, including the high-risk D+/R- patients.5-9 Upon completion of prophylaxis however, CMV infection and disease occurs in about 50% and 25-30% respectively of D+/R- SOT recipients within the first year after transplant \[30% rate of investigator treated CMV disease in PV16000\].9 The incidence of CMV infection following prophylaxis in D+/R- lung transplant recipients may be as high as 80%.10 As CMV disease occurring after prophylaxis will continue to impact morbidity and mortality in SOT recipients, it would be desirable to be able to predict which patient will develop this complication. Currently, there are no reliable methods that are routinely available to predict the risk of CMV infection or disease in an individual patient. CMV viral load testing after prophylaxis in D+/R- patients has been shown to have poor predictive value for subsequent CMV disease.11 CMV serology (a measure of humoral immunity) was also shown to be only of marginal use in predicting the risk of late onset disease.12 Cell mediated immunity (CMI) is known to be more important than humoral immunity in controlling CMV infection. CMV infection elicits a strong virus specific CD4+ and CD8+ T-cell response. CD8+ T-cell responses to the virus often contain multiple antigen-specific reactivities including to viral pp65 or IE-1 antigens as well as pp50, glycoprotein B, and IE-2 and other antigens.13 CD4+ T cells also play a part in CMV control via promotion of priming, expansion and maintenance of CD8+ CMV-specific CTLs.14 Measuring an individual's CMI response to CMV may be a useful predictor of the risk of CMV infection or disease after prophylaxis. Patients with a poor CMI response (especially a poor CD8+ T-cell response) could then be targeted with longer courses of antiviral prophylaxis.

Cell mediated immunity testing Most of the previous studies have focused on CTL responses to the CMV phosphoprotein pp65.15-17 However, since CD8+ T-cell responses to CMV often contain multiple antigen-specific reactivities, measurement of CMI using epitopes restricted to a single protein may not yield adequate results. In conjunction with Dr. Rajiv Khanna (Queensland Institute of Medical Research, Australia), and Cellestis Ltd (Sydney, Australia), we have done preliminary validation and assessment of a CMI (Quantiferon-CMV) assay in which we measure the IFN-γ responses to a range of T-cell epitopes of CMV viral proteins including pp65, pp50, the glycoprotein gB, and the immediate early IE-1 antigen that are specific for a wide range of HLA class I specificities \[See Appendix Table 1\]. The assay employs a peptide pool for stimulation of whole blood and is suitable for routine clinical use and evaluation in multicenter studies.

The Quantiferon-CMV assay has been compared to an ELISPOT assay in a study involving 37 healthy volunteers and 25 SOT recipients.18 In this study, the Quantiferon-CMV assay was at least as sensitive as the ELISPOT for some CMV epitopes, and more sensitive for other CMV epitopes. In addition, the Quantiferon-CMV results highly correlated with the CMV serostatus, in both healthy volunteers and transplant recipients. In another study,19 the Quantiferon-CMV assay was used in HIV-infected individuals with and without a history of CMV disease. The CMV specific immune response measured by the Quantiferon-CMV assay was higher in patients without a history of CMV disease, suggesting that a positive result of the Quantiferon-CMV may predict the likelihood for developing a protective immune response against CMV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytomegalovirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Male or female patients who fulfill the following criteria are eligible for inclusion.

* CMV D+/R- liver, kidney, heart, pancreas, lungor combined transplant recipients
* All eligible patients must be scheduled to receive 3 months of either valganciclovir, oral ganciclovir, or intravenous ganciclovir prophylaxis.
* Able to give written informed consent
* Are willing and able to comply with the protocol
* Age \>=18 years